Mark Venske Named New PAC Vice President of Sales and Support for the Americas

Fuel for thought

Mark Venske Named New PAC Vice President of Sales and Support for the Americas

14 Dec, 2011

Published over 14 years ago. See the latest and most current information on Fuel for thought.

PAC (USA) a global provider of advanced analytical instruments for laboratories and online process applications, is pleased to announce that Mark Venske has now joined the growing PAC team as the Vice-President of Sales and Support for the Americas. Mark has over thirty years of engineering, sales, and customer support experience from Spectra Tech Applied System and Varian, which was acquired by Agilent in 2010. Throughout his career, Mark has held various positions in sales, support, and business development.

“As we drive our technical expertise and product offerings, we continue to focus on bringing value to PAC customers and improving the overall customer experience,” said Mark. “PAC is focused on not just providing analytical instruments to clients, but providing holistic solutions that resolve analytical challenges. Our goal is to partner with our customers and help them solve key issues they face in today’s competitive landscape by improving productivity and the overall quality of their end products.”

“We at PAC are pleased that Mark has joined the team,” says Jeroen Schmits, PAC President. “With his extensive skills, knowledge, and experience, he will play a vital role to the improved success of PAC.”

Latest News

PIN 27.3 June/July 2026

Explore our Digital Edition

Discover the latest news and research

Digital edition

Explore Our Other Sites

Labmate Online
SERS bismuth nanoparticles sensor can spot lead ions in water at high sensitivity
Explore more Arrow
Envirotech Online
FM approval strengthens intelligent fixed gas detection for refineries and petrochemical plants
Explore more Arrow
Pollution Solutions Online
Slurry grant a fossil fuel failure?
Explore more Arrow
Chromatography Today
Unlock high-resolution analysis of therapeutic oligonucleotides
Explore more Arrow